Crizotinib, the first small-molecule kinase inhibitor, timely approved by Food and Drug Administration for the treatment of NSCLC patients (for details see FDA-US website), has limited activity against the various ALK-mutations identified in children with NB [14]. The gene discussed is ALK; the disease is neuroblastoma.